Imugene will forge ahead with a planned pivotal US trial for its blood cancer therapy Azer-cel, having recorded more ‘complete responses’ in its phase 1b study.

Let's Talk Business w/ Jeremy Rosen from TaxiBox 🚕📦
08:47

Money News with James Willis 💵📊📻 - Tuesday, 10th March
39:59

The "ridiculous" construction code hurting our housing dreams 🏠👷🏚️
08:52